NCT03706625: IDeATIon

Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

Completed Last updated 22 November 2023

What this trial tests

trial in Non Hodgkin Lymphoma in 201 participants. Completed in 6 July 2023.

Timeline

20 November 2018

Primary endpoint
6 July 2023

6 July 2023

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Completed
Study type	OBSERVATIONAL
Enrollment	201
Start date	20 November 2018
Primary completion	6 July 2023
Estimated completion	6 July 2023
Sites	1 location across France

Conditions studied

• Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
• Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
• Glioma — all drugs for Glioma →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Non Hodgkin Lymphoma or Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The explosion of novel therapies targeting tumor mutations or immune molecules requests to define or better characterize the mutational profiles of tumors that are none or insufficiently explored so far. This is particularly the case for tumors arising in immune-suppressed individuals or environments which have been poorly, if any, analyzed so far with modern molecular methods. The goal of the translational research program, Ideation, is to define novel biomarkers such as the tumor mutational profiling and immunomutanome in such contexts and to compare the results obtained to those observed in immune competent individuals. In addition, this approach will allow to characterize novel key non-invasive diagnostic and prognostic biomarkers such as circulating tumoral DNA and cells. Altogether results will provide novel biomarkers to better adapt therapeutic strategies in these cancers, to monitor response to treatment as well as to define new molecular targets of potential therapeutic strategies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Next Generation Sequencing Technology in Lung Cancer Diagnosis.
   Cainap C, Balacescu O, Cainap SS, Pop LA. · · 2021 · cited 62× · PMID 34571741 · DOI 10.3390/biology10090864
2. Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.
   Palacín-Aliana I, García-Romero N, Asensi-Puig A, Carrión-Navarro J, et al · · 2021 · cited 38× · PMID 34440110 · DOI 10.3390/biomedicines9080906
3. Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations.
   Bouzidi A, Labreche K, Baron M, Veyri M, et al · · 2021 · cited 7× · PMID 34710202 · DOI 10.3389/fcell.2021.661272
4. Integrating Artificial Intelligence, Circulating Tumor DNA, and Real-World Evidence to Optimize Hematologic Clinical Trials: Toward Adaptive and Learning Trial Designs.
   Mahmoud AM, Touti JP, Zaidi SR, Kodipad AA, et al · · 2026 · PMID 41976395 · DOI 10.3390/cancers18071173
5. OS01.4.A A DETECTABLE ANTITUMOR IMMUNE RESPONSE IS PRESENT IN GLIOMAS, BUT IS PROFOUNDLY DAMPED BY CHEMOTHERAPY
   · 2023
6. OS02.4.A IMPACT OF SURGERY ON SURVIVAL IN PATIENTS WITH MULTIPLE BRAIN METASTASES
   · 2023
7. OS01.5.A THE USE OF MULTIOMICS IN THE IDENTIFICATION AND CHARACTERISATION OF TERTIARY LYMPHOID STRUCTURES IN GLIAL TUMORS
   · 2023
8. OS02.5.A DEVELOPMENT OF A PATIENT DECISION AID FOR PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA - A CO-CREATION PROCESS
   · 2023